行情

TTPH

TTPH

Tetraphase制药
NASDAQ

实时行情|Nasdaq Last Sale

2.470
+0.010
+0.41%
休市 16:00 11/15 EST
开盘
2.450
昨收
2.460
最高
2.584
最低
2.360
成交量
8.09万
成交额
--
52周最高
39.60
52周最低
2.260
市值
670.81万
市盈率(TTM)
-0.0040
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TTPH 新闻

  • Edited Transcript of TTPH earnings conference call or presentation 12-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.1天前
  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.1天前
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.2天前
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.3天前

更多

所属板块

制药
+1.37%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

TTPH 简况

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
展开

Webull提供Tetraphase Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。